Contineum Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Contineum Therapeutics, Inc. (CTNM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.84M, a 58.81% increase year-over-year.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.82M, a 48.81% increase year-over-year.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.57M, a 12.13% increase year-over-year.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.42M, a 61.85% increase year-over-year.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.04M, a 47.53% increase from fiscal 2024.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.80M, a 206.62% increase from fiscal 2023.
- Contineum Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.22M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.84M 10-Q · filed 2026-07-30 | $7.66M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $3.82M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $10.04M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $2.57M 10-Q · filed 2025-10-30 | $4.99M derived: sum of 2 quarters · filed 2026-07-30 | $7.56M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $2.42M 10-Q · filed 2026-07-30 | $4.99M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $2.57M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $6.80M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.29M 10-Q · filed 2025-10-30 | $3.79M derived: sum of 2 quarters · filed 2025-10-30 | $4.55M derived: sum of 3 quarters · filed 2025-10-30 | |
| 2024-06-30 | $1.49M 10-Q · filed 2025-10-30 | $2.26M derived: sum of 2 quarters · filed 2025-10-30 | ||
| 2024-03-31 | $768.00K 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $2.22M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $477.00K 10-Q · filed 2024-11-06 | $966.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.46M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $489.00K 10-Q · filed 2024-11-06 | $983.00K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $494.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |